To assess the efficacy of a novel glycosylated mammalian cell derived recombinant human
interferon-(r-hIFN--1a) in the intralesional treatment of genital condylomata acuminata. The …

The number of clinic consultations for condylomata acuminata (genital warts) has increased
substantially during the last 30 years. Most infections produce benign lesions but a few types …

A randomized, double-blind, placebo-controlled trial was conducted to assess interferon-
beta efficacy and safety in the treatment of anogenital condylomatous lesions. One hundred …

Background: Interferon (IFN) alpha and IFN gamma have synergistic in vitro and in vivo
effects and have each been used in the treatment of anogenital condylomata acuminata …

An earlier study by this group failed to demonstrate significant therapeutic effect of 4 weeks
of systemic recombinant interferon (IFN)-α2 monotherapy on anogenital condylomata …

OBJECTIVE: To evaluate the safety and efficacy of two intralesional doses of recombinant
human interferon-beta (r-hIFN-beta: Rebif, Ares Serono), given 3 times a week for 3 weeks …

Fourteen patients with chronic genital warts were entered in a pair-matched crossover trial of
recombinant interferon-α-2a. They received daily doses of either 1.5× 106 U or 18× 106 U …

The activity of natural (leukocyte) interferon alfa in the treatment of condylomata acuminata
was assessed in a randomized, double-blind, placebo-controlled, multicenter trial. Interferon …

Background: Interferon in a variety of topical, interlesional, and parenteral preparations has
been used for condylomata acuminata (CA) in HIV negative patients. Study goals: This open …

Background: Pilot studies of adjuvant therapy with topically applied interferons (IFN) have
shown promising results in reducing the recurrence of condylomata acuminata (CA) …